COVID-19 resources / Clinical Research Insights and News

The Cohortias Blog

Stay informed

COVID-19 resources

Cohortias is bringing clinical research to Latin America, now proud to participate in COVID-19 clinical trials.

Our archive includes insights from our experts as they discuss lessons learned over the past three months in managing COVID-19’s impact on trials in Latin America and around the world.

Our blog posts provide insights into what companies should be doing now to prepare for the upcoming ‘new normal’.

oncology-clinical-trials

First-in-human – Treatment for metastatic or recurrent solid tumors.

Phase 1 trial evaluating XRD-0394 in combination with radiation therapy for the treatment of metastatic, locally-advanced or recurrent solid tumors has started.

clinical-trials-covid

Clinical Trials – The evolution in response to COVID-19.

The clinical trial landscape has arguably progressed more in the past 6 months than in the previous 10 years.

clinical-trials-Brazil

Clinical Trial Brazil – Treatment for arthritis in juvenile patients.

Xeljanz is said to be the first and only JAK inhibitor to receive approval in Europe for polyarticular JIA and juvenile PsA.

covid-latin-america-mexico

Positive Safety Report for new COVID-19 treatment trial.

Safety update on aviptadil which is being tested in the ACTIV-3 Critical Care Phase 3 study sponsored by the National Institutes of Health.

COVID-19 Research - Free Consultation

The clinical development journey is fraught with pitfalls and roadblocks; COVID-19 has almost overnight added to the complexity. Innovations, technologies and reinvented processes can help. Our experienced team of experts shares experiences, lessons learned and tips to help you mitigate risk in the current environment while implementing some of the industry’s latest innovations.

covid clinical trials

The presence of clinical research in Latin America has been growing steadily for the last decade, mainly because of cost effectiveness, excellent patient recruitment and the emergence of FDA approved regulatory agencies.